Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash from Investing Activities: 2011-2025

Historic Cash from Investing Activities for Abeona Therapeutics (ABEO) over the last 12 years, with Sep 2025 value amounting to -$64.6 million.

  • Abeona Therapeutics' Cash from Investing Activities fell 947.95% to -$64.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.3 million, marking a year-over-year increase of 345.45%. This contributed to the annual value of -$39.2 million for FY2024, which is 18965.38% down from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' Cash from Investing Activities is -$64.6 million, which was down 141.46% from $155.9 million recorded in Q2 2025.
  • Abeona Therapeutics' 5-year Cash from Investing Activities high stood at $155.9 million for Q2 2025, and its period low was -$64.6 million during Q3 2025.
  • Moreover, its 3-year median value for Cash from Investing Activities was $2.2 million (2023), whereas its average is $5.1 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 483.84% in 2021, then plummeted by 1,236.63% in 2023.
  • Abeona Therapeutics' Cash from Investing Activities (Quarterly) stood at $8.0 million in 2021, then tumbled by 416.16% to -$25.3 million in 2022, then skyrocketed by 145.59% to $11.5 million in 2023, then spiked by 63.73% to $18.9 million in 2024, then plummeted by 947.95% to -$64.6 million in 2025.
  • Its Cash from Investing Activities was -$64.6 million in Q3 2025, compared to $155.9 million in Q2 2025 and $4.2 million in Q1 2025.